Clearmind Medicine
- Country
- Ownership
- -
- Employees
- -
- Market Cap
- -
- Introduction
Clearmind Medicine, Inc. is a psychedelic pharmaceutical biotech company. It focuses on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize it as regulated medicines, foods, or supplements. The company was founded on July 18, 2017 and is headquartered in Vancouver, Canada.
Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Clearmind Medicine Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT05913752
- Locations
- 🇺🇸
Connecticut Mental Health Center, New Haven, Connecticut, United States
🇺🇸Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
🇮🇱The Sophie and Abram Stuchynski Israeli Alzheimer Medical Center, Ramat Gan, Israel
News
Clearmind Medicine's Psychedelic Combination Treatment for Cocaine Addiction Receives Patent Publication in South Korea
Clearmind Medicine announced the publication of a patent by the Korean Intellectual Property Office for its innovative MEAI and N-Acylethanolamines combination therapy targeting cocaine addiction.
Clearmind Medicine's CMND-100 Receives IRB Approval for AUD Clinical Trial at Yale
Clearmind Medicine received IRB approval for its Phase I/IIa clinical trial of CMND-100, a novel therapeutic targeting alcohol use disorder (AUD).
Clearmind Medicine Receives IRB Approval for CMND-100 Alcohol Use Disorder Trial
Clearmind Medicine has secured IRB approval for its Phase I/IIa clinical trial of CMND-100, a MEAI-based treatment for alcohol use disorder (AUD).